May 23, 2019
The Japanese Medical and Dental Practitioners for the Improvement of Medical Care (Hodanren) reiterated its push for more transparency in the pricing of Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel) in a statement issued on May 22 in conjunction with...read more